Section 3 of 6
Product information and disease description
242 evidence topics · 102 sources
Product description
Phase of product development
Regulatory status: Submission planned; registrational phase 3 EMERGE trial ongoing, with top-line results expected in the second half of 2028
Launch
No evidence found.
Planned update to EMERGE top-line guidance by the end of 2027
Orphan drug designation for myasthenia gravis, May 2026
Fast track or breakthrough therapy designation for generalized myasthenia gravis
No evidence found.
Phase 2 MaGic trial initiated after FDA IND clearance, February 2024
Phase 2 MaGic top-line results, September 2025
End-of-phase 2 meeting with the FDA, first quarter of 2026
FDA written feedback on antinuclear antibody screening and drug-induced lupus, March 2026
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Dianthus Therapeutics
Nonproprietary name: proposed and recommended international nonproprietary name
Brand name
No evidence found.
Structure: fully human IgG4-kappa antibody with an engineered Fc domain
Therapeutic class: classical complement pathway inhibitor targeting active C1s
Dosage forms and strengths
Intravenous loading dose followed by subcutaneous injection
Phase 3 subcutaneous presentation: prefilled syringe
Target commercial presentation: 300 mg/2 mL autoinjector
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
WHO INN class statement for claseprubart
WHO INN stem and target-class infix for monoclonal antibodies
WHO Anatomical Therapeutic Chemical group for complement inhibitors
AHFS class and ATC code assigned to claseprubart
No evidence found.
Indication
Indication under study: adults with acetylcholine receptor antibody-positive generalized myasthenia gravis
Eligible population: phase 3 EMERGE inclusion criteria
Size of the AChR antibody-positive population as the company states it
Pharmacology
Mechanism of action
Role of C1s in the classical complement pathway
Targeting of the small active fraction of circulating C1s
Binding selectivity for active C1s over proC1s
Upstream blockade of C3a, C3b, and membrane attack complex formation
Company description of the mechanism: latest statement
Pharmacodynamics
Classical pathway inhibition in healthy volunteers: phase 1
In vitro affinity and potency compared with riliprubart
| Assay | Claseprubart (DNTH103) | Riliprubart |
|---|---|---|
| Binding affinity to human active C1s, KD (KinExa) | “9pM” | “75pM” |
| Binding affinity to human active C1s, KD (SPR) | “8pM” | “35pM” |
| C4 cleavage by human active C1s, IC90 (nM) | “0.47” | “3.69” |
| Wieslab classical pathway assay in human serum, IC90 (μg/mL) | “0.45” | “5.4” |
| CH50 assay of RBC lysis in human serum, IC90 (μg/mL) | “98” | “668” |
| Liposome lysis in human serum, IC90 (μg/mL) | “14.7” | “39.8” |
Neurotransmission and muscle contraction in an in vitro myasthenia gravis model
Upstream versus downstream complement blockade: C3a, C3b, and membrane attack complex
Exposure and response in the MaGic open-label extension
Pharmacokinetics
Fc engineering for half-life extension
Phase 1 study design for pharmacokinetic assessment
Elimination half-life of approximately 60 days
Simulated steady-state exposure relative to the IC90
Observed steady-state concentration with 300 mg every 2 weeks: phase 2
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA written feedback on antinuclear antibody testing and the autoimmune risk description
Antinuclear antibody seroconversion: phase 2 randomized period
| Measure | Placebo (N=22) | Claseprubart 300mg/2mL Q2W (N=21) | Claseprubart 600mg/4mL Q2W (N=22) |
|---|---|---|---|
| Newly positive for anti-nuclear antibodies (ANA) | “0 (0%)” | “1 (5.9%)” | “8 (36.4%)” |
| Rashes | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Arthralgia | “1 (4.5%)” | “1 (4.8%)” | “0 (0%)” |
Antinuclear antibody testing removed from current trial protocols
Infection risk: rationale for sparing the lectin and alternative pathways
Infection risk: in vitro meningococcal killing assay
Infection and autoimmune events reported in clinical trials to date
Trial precautions: vaccination, complement deficiency, meningococcal history, and lupus
Extended half-life and duration of adverse effects
Special populations
Body weight ranges studied
Pregnancy and contraception requirements in trials
Pregnancy, lactation, renal function, and hepatic function: phase 1 exclusions
Drug/Drug, drug/disease interactions
Effects of other drugs on Claseprubart
Intravenous immunoglobulin: phase 1 Part C pharmacokinetic study
Prior FcRn blockers, complement inhibitors, rituximab, immunoglobulin, and plasma exchange: phase 2 exclusions
Prior B-cell therapies, immunoglobulin, and plasma exchange: EMERGE exclusions
Effects of Claseprubart on other drugs
No evidence found.
Dosing and administration
Dosage
EMERGE regimens: 300 mg every 2 weeks or every 4 weeks
MaGic regimens: weight-based loading dose then 300 mg or 600 mg every 2 weeks
Highest loading dose used in phase 2
Administration
Intravenous loading dose followed by subcutaneous injection
Prefilled syringe used in the phase 3 EMERGE trial
Target presentation: 300 mg/2 mL self-administered autoinjector
Formulation concentration and viscosity
Access and distribution
Contract manufacturing: WuXi Biologics
Cell line license and royalty on commercial supply from another manufacturer
Commercialization plans
Greater China license: Tenacia Biotechnology
Autoinjector device: SHL Medical Molly technology
Patent protection
Co-prescribed/Concomitant therapies
Medications excluded before randomization in the phase 3 trial
Required vaccination against encapsulated bacteria in the phase 3 trial
Medications excluded before randomization in the phase 2 trial
Required meningococcal vaccination in the phase 2 trial
Background immunosuppressive therapy at baseline in the phase 2 trial
| Characteristic | Placebo (N=22) | Claseprubart 300 mg every 2 weeks (N=21) | Claseprubart 600 mg every 2 weeks (N=22) |
|---|---|---|---|
| Baseline corticosteroid use, n (%) | “19 (86%)” | “17 (81%)” | “20 (91%)” |
| Number of immunosuppressive therapies at baseline: 1, n (%) | “11 (50%)” | “10 (48%)” | “12 (55%)” |
| Number of immunosuppressive therapies at baseline: more than 1, n (%) | “11 (50%)” | “11 (52%)” | “10 (45%)” |
| Neonatal Fc receptor blocker use in prior 24 months, n (%) | “0 (0%)” | “1 (5%)” | “0 (0%)” |
| Prior complement inhibitor use, n (%) | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Prior thymectomy, n (%) | “8 (36%)” | “6 (29%)” | “7 (32%)” |
Rescue therapy and acetylcholinesterase inhibitor use in the phase 2 trial
Effect of Claseprubart on quality measures
No evidence found.
Product comparison
Claseprubart: mechanism, route, dosing interval, and approval status
Complement C5 inhibitor: Soliris
| Attribute | Prescribing information |
|---|---|
| Product and route | “SOLIRIS® (eculizumab) injection, for intravenous use” |
| gMG indication | “the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Eculizumab, the active ingredient in SOLIRIS, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.” |
| Adult dosing and interval in gMG | “900 mg weekly for the first 4 weeks, followed by” |
| Adult dosing and interval in gMG, continued | “1,200 mg every 2 weeks thereafter.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2007” |
Complement C5 inhibitor: Ultomiris
| Attribute | Prescribing information |
|---|---|
| Product and route | “ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous use” |
| gMG indication | “the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.” |
| Mechanism of action | “Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity” |
| Dosing interval | “maintenance doses administered every 4 or 8 weeks, starting 2 weeks after loading dose.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2018” |
Complement C5 inhibitor: Zilbrysq
Neonatal Fc receptor blocker: Vyvgart
| Attribute | Prescribing information |
|---|---|
| Product and route | “VYVGART® (efgartigimod alfa-fcab) injection, for intravenous use” |
| gMG indication | “VYVGART is a neonatal Fc receptor blocker indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).” |
| Mechanism of action | “Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Dosing and interval | “The recommended dosage is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks.” |
| Treatment cycles | “Administer subsequent treatment cycles based on clinical evaluation.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2021” |
Neonatal Fc receptor blocker: Vyvgart Hytrulo
| Attribute | Prescribing information |
|---|---|
| Product | “VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase” |
| gMG indication | “generalized myasthenia gravis (gMG)” |
| Mechanism of action | “Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Route | “VYVGART HYTRULO is for subcutaneous use only.” |
| Self-administration | “Prefilled syringe can be administered by patients and/or caregivers.” |
| gMG dosing interval | “Administer in cycles of once weekly injections for 4 weeks.” |
| gMG dose, prefilled syringe | “Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over 20 to 30 seconds.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |
Neonatal Fc receptor blocker: Rystiggo
Neonatal Fc receptor blocker: Imaavy
CD19-directed B-cell depleting antibody: Uplizna
Place of product in therapy
Disease description
Definition and etiology
Definition: autoantibody-mediated disorder of neuromuscular transmission
“Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MG is considered a classic example of antibody-mediated autoimmune disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These autoantibodies disrupt cholinergic transmission between nerve terminals and muscle fibers by causing downregulation, destruction, functional blocking of AChRs, or disrupting the clustering of AChRs in the postsynaptic membrane.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Localized or general muscle weakness is the predominant symptom and is induced by the antibodies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients are grouped according to the presence of antibodies, symptoms, age at onset and thymus pathology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Generalized and ocular forms
“MG presents in two forms: ocular (oMG), affecting the levator palpebrae superioris, orbicularis oculi, and extraocular muscles, and generalized (gMG), involving bulbar, axial, limb, and respiratory muscles” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients have generalized weakness affecting the extraocular, bulbar, trunk, and extremity muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 20% of MG patients, the muscle weakness remains confined to the extraocular muscles” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is the prototypic autoimmune disease most commonly caused by antibodies to the acetylcholine receptor (AChR) leading to characteristic fatigable weakness of the ocular, bulbar, respiratory, axial, and limb muscles.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: autoantibody subgroups
“Antibodies against the AChR are found in approximately 80% of MG patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AChR antibodies are predominantly of the IgG1 and IgG3 subclasses” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Antibodies against MuSK are found in approximately 7–10% of all MG patients and up to 40% of patients with generalized MG who are seronegative for AChR Abs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lrp4 antibodies are present in 2–50% of double seronegative MG cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In around 10% of patients with generalized MG, no antibodies are detected by standard testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many of these patients have low‐concentration or low‐affinity AChR antibodies when tested with more sensitive methods” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: thymus pathology and age at onset
“Most MG patients have pathogenic autoantibodies against the extracellular part of acetylcholine receptors (AChR), commonly associated with an abnormal thymus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thymoma is present in 10% of such patients, and thymic hyperplasia with ectopic germinal centers appears in most patients with symptom onset before age 50 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Early-onset MG (EOMG) corresponds to patients presenting before age 50.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Late-onset MG (LOMG) is defined by onset after the age of 50.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MG is the most common paraneoplastic disorder associated with thymoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conversely, 10–20% of patients with MG have thymomas” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: genetic susceptibility
“There is frequent association of A1-B8-DR3 haplotype with early-onset MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A large genome-wide association study involving patients from North America and Italy identified different haplotypes across the HLA region, cytotoxic T-lymphocyte-associated protein 4 gene (CTLA4) and tumor necrosis factor receptor 4 superfamily, member 11a, (TNFRSF11A) and NFκB activator genes in early- and late-onset MG cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Generalized myasthenia gravis
United States, 2021 claims and electronic health records: incidence of all myasthenia gravis
“Data were extracted from the Clarivate Real-World Data Repository (2016-2021), a US claims and electronic health records database.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The diagnosed prevalence and incidence of MG in the United States in 2021 were calculated to be 37.0 per 100,000 persons and 3.1 per 100,000 persons, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While the incidence and prevalence of MG increased with age in both men and women, higher prevalence and incidence of MG were observed in younger women (<50 years) compared with men of matching age, and in older men (≥65 years) compared with women of the same age group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States, 2017 commercial, Medicare, and Medicaid claims: incidence of all myasthenia gravis
“From the US commercially/Medicare-insured cohort, we calculated an age-and sex-standardized incidence of 68.5 new cases per million person-years with an adjusted prevalence of 316.4 per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within the Medicaid-insured population, similar yet slightly lower numbers emerged: the adjusted incidence was 49.7 new cases per million person-years, and the adjusted prevalence rate was 203.7 cases per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We extrapolated this to calculate the overall US prevalence of 320.2 per million people and an incidence of 54 per million person-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States, Medicare fee-for-service beneficiaries aged 65 years and older: incidence of all myasthenia gravis, 2008 to 2019
“Study-eligible beneficiaries were aged 65 years and older, had at least 1 month of FFS Part A/B coverage, and were without any health maintenance organization insurance coverage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MG incidence increased from 12.2 to 13.3 per 100,000 PYs from 2008–2009 to 2018–2019 (p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Taiwan, 2009 to 2019: incidence of generalized myasthenia gravis
“There was no temporal trend in all-cause fatality rates (range 2.76–3.79/100 patients annually) or gMG incidence rates (2.4–3.17/100,000 population annually).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 2019, the annual prevalence of gMG was 11.18 per 100,000 population and the incidence rate was 2.95 per 100,000 population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Canada, Ontario, 2013 to 2020: incidence of all myasthenia gravis
Global systematic review of studies through February 2024: incidence of all myasthenia gravis
“Incidence rates ranged from 2.3 to 61.3 cases per million person-years, with a mean incidence of 15.7 (95% CI: 11.5–19.9) and a median of 13.3 cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies showed increasing rates over the years (Fig. 4): considering the period 1967–2007, the mean IR was 8.7 (95% CI: 5.5–11.9; range: 2.3–21.3) cases per million person-years, and in the period 2008–2022, the mean IR has more than doubled: 22.9 (95% CI: 14.1–31.7; range: 6.3–61.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The American countries showed the highest mean IR cases per million person-years with a value of 23.7 (95% CI: 6.5–40.9; range: 4.7–61.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global systematic review of studies from 1950 to 2007: pooled incidence of all and AChR antibody-positive myasthenia gravis
“55 studies performed between 1950 and 2007 were included, representing 1.7 billion population-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IR ranged from 1.7 to 21.3 cases per million person-years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled estimate IR (eIR) was calculated as 5.3 per million person-years (C.I.: 4.41 - 6.12).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AChR MG IR ranged from 4.3 to 18.0 per million person-years with a pooled AChR MG eIR of 7.3 per million person-years (C.I.: 5.5, 7.8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Generalized myasthenia gravis
United States, 2021 claims and electronic health records: diagnosed prevalence of all myasthenia gravis
“The diagnosed prevalence and incidence of MG in the United States in 2021 were calculated to be 37.0 per 100,000 persons and 3.1 per 100,000 persons, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The updated prevalence and incidence of MG in the United States in 2021 are higher than previous reports from the 1980s and early 2000s, following a global trend of increased prevalence and incidence for this disorder in the last few decades.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States, 2017 claims and 2021 extrapolation: prevalence and number of adults with all myasthenia gravis
“Using a previously validated algorithm, we identified cases of MG in two Truven Health MarketScan databases, which during 2017 included a sample of approximately 20 million commercially insured and Medicare recipients, plus 10 million Medicaid recipients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From the US commercially/Medicare-insured cohort, we calculated an age-and sex-standardized incidence of 68.5 new cases per million person-years with an adjusted prevalence of 316.4 per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within the Medicaid-insured population, similar yet slightly lower numbers emerged: the adjusted incidence was 49.7 new cases per million person-years, and the adjusted prevalence rate was 203.7 cases per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given our results, we were able to estimate that there were approximately 82,715 US adults living with MG in 2021 (or an estimated 320.2 cases per million adults in the USA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States, Medicare fee-for-service beneficiaries aged 65 years and older: prevalence of all myasthenia gravis, 2006 to 2019
“The period prevalence of MG increased from 81 to 119 per 100,000 FFS A/B population from 2006–2007 to 2018–2019 (p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing trends of prevalence were observed in all sex (male/female), age (65–69/70–74/75–79/80+), race/ethnic (African American/Asian/Hispanics of any race/non-Hispanic White/other), and census region (Northeast/Midwest/South/West) subgroups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global meta-analysis of 63 studies: prevalence of all myasthenia gravis
“After deleting articles unrelated to the research question, finally, 63 articles with a sample size of 1,206,961,907 people were included in the meta-analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of MG worldwide was estimated to be 12.4 people (95% CI 10.6–14.5) per 100,000 population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“which has the highest prevalence in the Americas with 19 people (95% CI 15–23.8)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global systematic review of studies through February 2024: prevalence of all myasthenia gravis
“Prevalence of MG ranged from 20 to 475 cases per million, with a mean prevalence of 173.3 (95% confidence interval [CI]: 129.7–215.5) cases per million and a median prevalence of 129.6 cases per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean PR was 97.5 (95% CI: 59.9–141.9; range: 20–174.2) cases per million considering studies from 1952 to 2007 (the most recent period investigated by the last systematic review [7]), while the mean PR increased up to 220.1 (95% CI: 149.3–288.1; range: 78–475) cases per million considering the period 2008–2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“North America showed a mean PR of 341.4 (range: 142–475) cases per million” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most of the included studies (81.9%) examined all types of MG (ALL MG), reporting prevalence (59 studies), incidence (50 studies), and mortality (16 studies).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global systematic review of studies from 1950 to 2007: pooled prevalence of all myasthenia gravis
“The observed PR ranged from 15 to 179 per million” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated pooled PR is 77.7 cases per million (C.I.: 63.98, 94.30) but, as for IR there was marked heterogeneity with I2 = 98% (C.I.: 97-98%) observed across studies limiting interpretation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Taiwan, 2009 to 2019: prevalence of generalized myasthenia gravis
“The number of patients with gMG increased from 1,576 in 2009 to 2,638 in 2019 and the mean (standard deviation) age from 51.63 (17.32) to 55.38 (16.29) years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of patients with gMG increased annually from 6.83/100,000 population in 2009 to 11.18/100,000 population in 2019 (p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The total number of patients with MG (ocular or generalized) increased from 3,647 in 2009 to 6,293 in 2019, with prevalence rates that increased annually from 15.80 per 100,000 population to 26.67 per 100,000 population, a 1.7-fold increase over the study period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Canada, Ontario, 2013 to 2020: prevalence of all myasthenia gravis
Natural history, survival, and mortality
Natural history: progression from ocular to generalized disease
“In addition, up to 80% of patients with ocular onset will go on to develop generalized symptoms, usually within two years of disease onset” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A recent population-based study conducted by the Mayo Clinic found that 51% of patients presented with ocular onset, and 55% of these developed generalized symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the remaining, 90% will continue to have ocular manifestations only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hence, ocular MG is defined by isolated extra-ocular involvement for a period of ≥2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: severity peaks early, and exacerbations recur
“Between 1940 and 2000 a total of 1976 patients with myasthenia gravis (MG) were studied.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most severe level of weakness and high mortality occurred during the first 1 to 2 years of the disease, after which many patients experienced improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: spontaneous remission
“Spontaneous remissions for different lengths of time may occur in the course of adult-onset MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In an earlier study conducted before the widespread use of steroids and other immunosuppressants, approximately one fourth of the patients had a complete or near complete spontaneous remission, lasting an average of 4.6 years and up to 17 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Half of the remissions occurred during the first year after onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: global systematic review
“showing a mean MR of 1.4 (95% CI: 0.8–2.1; range: 0.5–3.5) cases per million person-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No trend was observed for MR over the years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: United States hospitalizations, 2010 to 2019
“Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality among patients aged 65 years or older was higher compared with that in all patients, averaging 5.0% across each of the study years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: United States hospitalizations, 2000 to 2005
“The overall in-hospital mortality rate was 2.2%, being higher in MG crisis (4.47%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Older age and respiratory failure were the predictors of death, with adjusted odds ratios of 9.28 (95% confidence interval [CI], 3.31, 26.0) and 3.58 (95% CI, 2.01, 6.38).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality and survival: United States Medicare beneficiaries aged 65 years and older
“All-cause mortality among MG beneficiaries was stable from 6.26 deaths per 100 PYs in 2006–2007 to 5.67 in 2018–2019 (p = 0.18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohorts of 6024 incident MG and 30,083 control beneficiaries were Included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mortality rate was higher in the MG cohort compared to controls (66.8 vs. 57.1 per 1000-person-year, p < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for time-varying CCI, no significant difference in survival was observed between two cohorts (adjusted hazard ratio 1.09 [0.87-1.36], p = 0.47).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen percent of deaths in the MG cohort were attributed to MG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to the non-MG cohort, mortality rates (per 1000-person-year) specific to infections were higher among the MG cohort (2.0 vs. 1.2) while malignancies and dementia-specific mortality rates were lower (10.3 vs. 12.5 and 4.7 vs. 7.2), all p < 0.01.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: Denmark nationwide cohort, 1985 to 2020
“Our cohort encompassed 2,110 patients (50.2% female) and 21,100 from the general population, with 77.3% aged younger than 75 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Short-term cumulative mortality was 4.8% in patients with MG and 2.6% in the general population, yielding a HR of 1.8 (95% CI 1.5-2.3). Long-term mortality was 1.3 (95% CI 1.1-1.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Comorbidity-adjusted analyses decreased short-term mortality (HR 1.6, 95% CI 1.3-2.0), and long-term mortality aligned with the general population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: Taiwan, generalized myasthenia gravis, 2009 to 2019
Survival: Ontario, Canada, with and without myasthenic crisis
“Myasthenic crisis occurred in 8.9% of individuals over the study, with a post‐diagnosis incidence rate of 2.6 per 100 person‐years and 30‐day mortality of 28.1%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“5‐year overall survival was 75%, declining to 39% among those with crisis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: Israel, tertiary center cohort, 2000 to 2023
“Myasthenia Gravis mortality was 14% at 5 years (61/422) and 21% at 10 years (87/422).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality was significantly higher than control groups (p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intubations during myasthenic crisis were linked to higher mortality (p = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Neuromuscular junction: reduced acetylcholine receptors and sodium channels
“In addition, there is a reduction in the number of AChRs and voltage-gated sodium channels as the result of complement-related injury to the postsynaptic membrane in MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The resultant inefficient neuromuscular transmission is reflected in decremental response in the amplitude of compound muscle action potential (CMAP) during repetitive nerve stimulation (RNS) and abnormal jitter or blocking in single fiber EMG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AChR antibodies: complement fixation, antigenic modulation, and receptor blockade
“The predominant mechanism is the binding of the antibody and activation of the complement cascade, leading to the formation of the membrane attack complex (MAC), which causes damage of the postsynaptic membrane and destruction of synaptic folds which contain AChRs and associated proteins, including voltage-gated sodium channels” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other mechanisms of pathogenicity include: (1) antigenic modulation by the binding and crosslinking of AChRs, leading to increased endocytosis and degradation [37]; and (2) the impairment of AChR function, either by the blocking of ACh binding to the receptor [38] or the prevention of channel opening” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anti-AChR autoantibodies belong to the IgG1 and IgG3 subclasses, that are the strongest activators of the complement system.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Indeed, pathogenicity of these autoantibodies, but not that of anti-MuSK antibodies that belong to IgG4, is mainly due to complement fixation at the NMJ ultimately leading to postsynaptic membrane destruction and impairment of the neuromuscular transmission” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement: classical pathway initiation at the endplate
“In MG, complement-mediated damage of the NMJ occurs via the classical complement pathway, which starts with C1q binding to the Fc domain of the autoantibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Critical steps of the complement cascade are then the cleavage of C3 into C3a and C3b, and of C5 in C5a and C5b, the latter leading to the formation of the membrane attack complex (MAC, C5bC6C7C8C9 also known as C5b-9) that causes focal lysis of the post-synaptic membrane, disruption of post-junctional folds, and ultimately reduction of functional AChRs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In MG, the classical pathway is involved by the initiation of the antigen/antibody complex being recognized by C1q.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The C1q forms a pentameric complex with the C1r2C1s2 serine protease tetramer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C2 also becomes cleaved by C1s to form the C3 convertase (C4b2a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement: deposition at the endplate in patients
“In muscle biopsies from MG patients, IgG and C3 deposition was localized at identical sites of post-synaptic membrane, and specifically on debris of junctional folds in the synaptic clefts and disintegrating junctional folds” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Deposition of C9, the main component of the final and stable MAC, was also observed at the MG end plate regions, with the most intense depositions associated with the destroyed NMJs, indicating that NMJ loss may be largely due to complement activation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with anti-AChR+ MG have autoantibodies and MACs present at NMJs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Damaged NMJs are associated with more severe disease, fewer AChRs, and MACs in synaptic debris.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complement: evidence from experimental autoimmune myasthenia gravis
“Mice deficient in C3 and C4 demonstrate reduced clinical scores compared to their wild-type littermates during the course of active EAMG, with C3-knockout mice showing no signs of weakness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Complement-deficient EAMG animals showed a preservation of AChR density at the neuromuscular junction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C5-deficient mice demonstrated reduced incidence of disease compared to the C5-sufficient mice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies in animals lacking specific complement proteins have confirmed that MAC formation is required to induce experimental autoimmune MG (EAMG) and NMJ damage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Complement inhibition in EAMG models can prevent disease induction and reverse its progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complement: C1s and classical pathway activation in patients
“The C1-inhibitor (C1-INH) regulates the classical pathway and is a promising marker in other autoimmune disorders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Serum and plasma C1s-C1-INH levels were higher in MG patients than in matched healthy controls, supporting early classical pathway activation in most MG patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These findings allow prospective validation studies of activated C1s as a putative treatment target and potential accompanying biomarker in MG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Circulating complement protein profile may be used as a biomarker for evaluating patient-specific complement activation: (i) Romi and colleagues found reduced C3 and C4 serum levels in AChR-MG patients with high autoantibody titers, indicating increased in vivo complement consumption” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement: heterogeneity of complement dependence and response to C5 inhibition
“By means of this system, they observed a subset of AChR-MG patients with high complement activity, who are likely patients in whom complement activation is the major disease mechanism, whereas the remaining patients showed low activity, reflecting possible complement-independent autoantibody-mediated mechanisms of NMJ damage” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To date, all FDA-approved drugs in this category focus on targeting the C5 convertase enzyme.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to note that in MG there is no evidence suggesting a role for C5a in the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There remain upward of thirty percent of patients who do not benefit from complement inhibition, which demonstrates the importance of other mechanisms of autoantibody action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MuSK and LRP4 antibodies: complement-independent mechanisms
“MuSK antibodies belong mainly to the IgG4 subclass.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“They do not fix complement and are not strong activators of cell-mediated cytotoxicity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mechanism by which MuSK antibodies exert their pathogenic effect on the neuromuscular junction is via binding to the Ig-like domain of the protein, preventing its phosphorylation, and subsequently disrupting the Agrin-Lrp4-MuSK-Dok-7 signaling pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The LRP4 antibodies are primarily IgG1 and IgG2 subtypes and follow similar clinical presentation to a mild form of early-onset MG (22), inhibit clustering of AChR, and appear not to strongly activate complement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Clinical diagnosis and confirmatory testing
“The diagnosis of autoimmune Myasthenia Gravis (MG) remains clinical and rests on the history and physical findings of fatigable, fluctuating muscle weakness in a specific distribution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ancillary bedside tests and laboratory methods help confirm the synaptic disorder, define its type and severity, classify MG according to the causative antibodies, and assess the effect of treatment objectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diagnosis is straightforward in most patients with typical symptoms and a positive antibody test, although a detailed clinical and neurophysiological examination is important in antibody-negative patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Antibody testing: AChR antibodies
“In a patient with clinical features of MG, serum testing for AChR-Ab is the first recommended step in diagnosis by most recent guidelines and expert opinions” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The test has a very high specificity, so the detection of elevated titers in the appropriate clinical setting is diagnostic of AChR-myasthenia, and further testing may not be necessary” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The RIPA for binding Ab is abnormal in up to 85% of adult patients with generalized MG, but only about 50% of patients with ocular MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The technique detects autoantibodies to clustered AChR in about 15% of RIPA-seronegative MG patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody testing: MuSK and LRP4 antibodies and seronegative disease
“MuSK-Ab are found in about 6–8% of all MG cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In approximately 15% of patients with generalized MG and 50% of patients with ocular MG, both AChR and MuSK antibodies were absent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Detection rates in double-seronegative patients range from 2% to 50%, depending on the geographical origin, with LRP4-Ab being more frequent in non-Caucasian patients, and on the employed assay, with Live CBA being the most widely used” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody testing: United States testing patterns after a new diagnosis
“Of 5788 cases, 2590 (44.7 %) had at least one valid serology test result: 1453 (56.3 %) seronegative, 1094 (42.4 %) anti-AChR+, 28 (1.1 %) anti-MuSK+, and 5 (0.2 %) anti-LRP4+.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among the seronegative, 56.6 % were only tested for anti-AChR antibodies, 33.7 % tested both anti-AChR and anti-MuSK antibodies, and 5.0 % tested all three antibodies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Electrodiagnosis: repetitive nerve stimulation
“In generalized MG, RNS of distal muscles is abnormal in 30–35% of patients, while in proximal muscles, it is abnormal 60–70%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One should note as a standard feature the high specificity of RNS, which reaches about 97% in generalized MG and 94% in ocular MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Electrodiagnosis: single-fiber and concentric needle jitter
“The jitter study is the most sensitive indicator of impaired neuromuscular transmission” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CNE jitter is abnormal in 98–100% in generalized MG and above 90% in ocular MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While highest in sensitivity, jitter measurements are not specific and may be abnormal in other synaptic disorders, in denervation and reinnervation processes (poly- and mononeuropathies), some myopathies, and with motor neuron disorder (MND) in particular” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bedside tests: ice-pack and edrophonium tests
“The test is used mostly in ocular MG and seems more popular among neuro-ophthalmologists; some authors report sensitivities equal to that of single-fiber electromyography (SFEMG) in patients presenting with ptosis and a very high negative predictive value” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, others note much lower specificity at about 25%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the USA, edrophonium has been discontinued since 2018” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MGFA clinical classification
Consensus definitions: treatment goal, remission, crisis, and refractory disease
“MMS: The patient has no symptoms or functional limitations from MG but has some weakness on examination of some muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rapid clinical worsening of MG that, in the opinion of the treating physician, could lead to crisis in the short term (days to weeks).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Worsening of myasthenic weakness requiring intubation or noninvasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PIS3 is unchanged or worse after corticosteroids and at least 2 other IS agents, used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning, as defined by patient and physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay: United States patients with generalized myasthenia gravis
“Quantitative surveys and qualitative interviews were conducted (January-May 2023) in patients with gMG (n = 71 surveys; n = 47 interviews) and clinicians in the United States treating patients with gMG (n = 12 surveys and interviews).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had mean (SD) diagnostic journey time of 11.8 (22.5) months from symptom onset to seeking care and 15.5 (36.7) months from seeking care to diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sources of diagnostic journey delay (≥9.9 % patients) were: clinicians mistaking gMG symptoms as female health issues, difficulty accessing specialty care, and lack of gMG knowledge among HCPs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Core feature: fatigable, fluctuating, predominantly proximal weakness
“The core clinical manifestation of MG is fatigable muscle weakness, worsened by exertion and improved by rest.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Muscle weakness fluctuates over time and increases with repeated or sustained muscle use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The weakness is more pronounced in proximal than distal muscles, and leg muscles are typically mildly weak or unaffected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The weakness is symmetrical, apart from the eyes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ocular symptoms: ptosis and diplopia
“The most common presenting symptoms are ocular, with double vision and ptosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients will develop diplopia and/or ptosis some time during the course of their disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bulbar symptoms: dysarthria, dysphagia, and facial and jaw weakness
Axial symptoms: neck weakness and head drop
“Axial weakness can also be present, with neck flexion weakness usually more common than weakness of neck extension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a previous retrospective study from our center, about 10% of MG patients developed head-drop some time during the disease course” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Head-drop was associated with age >60 and male patients in that study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limb symptoms: proximal and, less often, distal weakness
“Limb muscle weakness tends to be symmetric and proximal, and patients commonly complain of difficulty climbing stairs, getting up from chairs, and raising arms above their head.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In some instances, distal muscles can be predominantly affected, either in a symmetric or asymmetric distribution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported symptoms: frequency and most bothersome symptoms
“Semi-structured, in-depth concept-elicitation interviews were conducted with 28 individuals diagnosed with gMG in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants reported gMG symptoms that affected many body regions and functions, with an average of 16 symptoms per participant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequently reported symptoms were eyelid drooping (93%), physical fatigue (89%), symptoms affecting the legs (82%), difficulty breathing (82%), and difficulty holding head up (82%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants’ most bothersome symptoms were blurry/double vision (43%), breathing difficulties (36%), all-over fatigue (36%), and swallowing problems (29%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Symptoms by antibody subgroup: MuSK antibody-positive disease
“Muscle weakness preferentially affects cranial and bulbar muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over 40% of patients present with bulbar weakness, usually associated with neck and respiratory involvement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“About 30% of patients present with diplopia and/or ptosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limb weakness can be uncommon, but when present it tends to be severe and associated with muscle atrophy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Myasthenic crisis: frequency, triggers, and outcomes
“Myasthenic crisis (MC) is a life-threatening manifestation of myasthenia gravis (MG) defined by respiratory insufficiency that requires the use of invasive or non-invasive ventilation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MC occurs in approximately 15%-20% of patients with MG usually within the first 2 to 3 y of the disease course.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Many crises have a specific trigger with respiratory infections being most common; however, no specific trigger is found in 30%-40% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MG patients with a history of MC, severe disease, oropharyngeal weakness, muscle-specific kinase (MuSK) antibodies and thymoma appear to be at higher risk.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mortality rate in United States cohorts is less than 5% and mortality in MC seems to be driven by age and other medical co-morbidities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A myasthenic crisis (MC) is a more severe, life-threatening escalation of muscle weakness that leads to respiratory failure, necessitating intensive care unit admission with assisted ventilation, usually requiring an inpatient stay period of several weeks, often in the range of 2–4 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 20% of patients with gMG are estimated to experience MC during a period of 3 years or longer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Myasthenic crisis: Ontario, Canada, population-based incidence
Exacerbations and crises: predictors and inpatient use, United States generalized myasthenia gravis
“Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After re-weighting, patients with a clinical event had higher number of inpatient admissions [rate ratio (RR) = 6.02], emergency visits (RR = 1.91), and outpatient visits (RR = 1.58; all p < 0.05) in the 12 months post-index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization trends: United States, 2010 to 2019
“Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Refractory disease: persistent moderate or severe weakness
Glucocorticoid toxicity: United States commercially insured adults with generalized myasthenia gravis
“Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the study period, incident GC toxicities were more common among patients in the any GC use cohort than the no GC use cohort (61.9% vs 52.3% with ≥1 toxicity), with a trend of increasing incidence with increasing GC use (≥5 mg/d: 62.9%; ≥10 mg/d: 67.3%; all P < .001” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, a greater proportion of patients with any GC use than no GC use had ≥3 incident GC toxicities (16.5% vs 9.5%), with this proportion rising with mean PEDD ≥5 mg (18.9%) and mean PEDD ≥10 mg (22.8%; all P <.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both acute and chronic incident GC toxicities were more common in the any GC use cohort than the no GC use cohort (acute: 28.5% vs 19.1%; chronic: 51.9% vs 43.8%; both P <.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since claims data do not contain reasons for diagnoses, toxicities could not be confirmed to be related to GC use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid toxicity: recognized adverse effects and higher-risk patients
Burden of Generalized myasthenia gravis
Humanistic burden and health-related quality of life
Patient-reported burden by MGFA class: MyRealWorld MG baseline, seven countries
“Adult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline results of 841 participants (mean age 47 years, 70% women) are reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I–IV.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health utilities and medical care use compared with the general population
“In MRW ( n = 1859), 58.4% of respondents had moderate-to-severe MG. Average utility values were lower in MRW versus POPUP (0.739 vs. 0.843 for EQ-5D-5L; 0.493 vs. 0.746 for HUI3), and declined with more severe disease (0.872, 0.707, 0.511 EQ-5D-5L utilities and 0.695, 0.443, 0.168 HUI3 utilities for mild, moderate, and severe MG, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Use of medical care was twice as likely in MRW in comparison with POPUP (51.9% vs. 24.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life and support needs in U.S. adults receiving standard of care without advanced biologics
“Patients had received treatment with standard of care (acetylcholinesterase inhibitors, non-steroidal immunosuppressants, corticosteroids, rituximab, immunoglobulins, plasmapheresis) but not advanced biologics (eculizumab, ravulizumab, zilucoplan, efgartigimod, rozanolixizumab, nipocalimab).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 157 eligible patients completed the survey (87.3% female, mean [SD] age 49.5 [14.4] years, mean [SD] time since diagnosis 11.0 [10.9] years). Mean (SD) MG-QoL-15R score was 16.2 (7.2), EQ5D-5L score was 0.6 (0.3), and FACIT-fatigue subscale score was 20.2 (11.3). Overall, 51.6% received additional support/care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with moderate/severe gMG (136/157 [86.6%]) had greater symptom occurence, reduced treatment satisfaction, greater health-related quality of life impairment, and greater support/care needs, compared with patients with mild gMG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Life domains affected in U.S. patients and caregivers
“across 8 life domains (occupation, financial, emotional, physical, sleep, social, planning and autonomy, and safety)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents included 239 patients with gMG (63%, aged 18–49 y; 69%, female) and 81 caregivers (58%, aged 18–49 y; 42% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 5 domains most impacted by gMG were occupational (mean domain score [SD]: 4.0 [1.2]), planning and autonomy (4.0 [1.1]), financial (3.9 [1.2]), physical (3.9 [1.1]), and sleep (3.9 [1.2]) for patients and financial (3.7 [1.2]), sleep (3.7 [1.1]), occupational (3.6 [1.2]), planning and autonomy (3.6 [1.1]), and safety (3.6 [1.1]) for caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible patients were aged ≥ 18 years currently living in the United States with a self-reported physician diagnosis of gMG regardless of antibody status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of psychological symptoms and health-related quality of life
“Sixty-seven publications were included in the SLR. Compared with the general population, patients with MG experienced worse HRQoL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, in general those with more severe symptoms and hospitalization days had worse depression and anxiety, and fatigue and sleep improved with disease remission and/or improvement. Scores were worse for females compared with males and where evaluated, HRQoL scores generally improved following treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Incremental annual costs of newly diagnosed gMG compared with matched controls: U.S. claims, 2017 to 2023
“Adults with newly diagnosed gMG were identified from Komodo Research data (January 1, 2017, to September 30, 2023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The gMG cohort (mean follow-up = 32.7 months) compared with the non-MG cohort (mean follow-up = 31.3 months) had 2.4, 1.6, and 1.9 times more inpatient days, emergency department visits, and outpatient visits annually, respectively (all P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean annual all-cause total health care costs in the gMG cohort were $43,872 higher than in the non-MG cohort ($58,341 vs $14,469; P < 0.001); 59.3% of the difference was driven by pharmacy costs (mostly immunoglobulin).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prediagnosis weakness and fatigue symptoms, exacerbation or crisis, and use of immunoglobulin were important factors significantly associated with high health care costs in the gMG cohort (all P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs associated with exacerbations and crises in newly diagnosed gMG: U.S. claims
“Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After re-weighting, patients with a clinical event had higher number of inpatient admissions [rate ratio (RR) = 6.02], emergency visits (RR = 1.91), and outpatient visits (RR = 1.58; all p < 0.05) in the 12 months post-index. Mean total healthcare costs were $70,792 higher among patients with a clinical event ($95,821 vs. $25,029, p < 0.001), driven by immunoglobulin and inpatient costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incremental costs and event-related costs in prevalent and incident gMG: U.S. claims, 2017 to 2023
“Analyses included 16,561 gMG patients (12,813 prevalent and 3748 incident) and 105,716 non-gMG controls. Among prevalent and incident gMG patients, respectively, MG exacerbation occurred during follow-up in 12.2 and 22.0% and myasthenic crisis in 6.0 and 12.4%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After weighting, gMG patients (median follow-up 696 days) experienced more frequent all-cause HCRU encounters and >4-fold higher healthcare costs ($5420 PPPM or ∼$65,000 per annum) versus non-gMG controls ($1298 PPPM or ∼$15,500 per annum).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among MG patients, those with MG exacerbation/myasthenic crisis, respectively, experienced means of 3.02/3.35 hospitalizations, 1.91/2.13 emergency department encounters, 12.70/13.39 skilled nursing facility encounters, and 67.86/75.52 outpatient encounters during follow-up; associated costs were $17,113/$18,640 PPPM (or ∼$205,000/$224,000 per annum).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incremental monthly costs and the effect of comorbidities and acute events: U.S. claims, 2017 to 2021
“The gMG and matched non-MG cohorts each contained 2,739 patients. Mean incremental healthcare costs associated with MG were $4,155 (gMG: $5,567; non-MG: $1,411), with differences driven by incremental inpatient costs of $2,166 (gMG: $2,617; non-MG: $452); all p < 0.001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with gMG in cardiometabolic (n = 1,859), psychiatric (n = 1,308), and exacerbation/crisis (n = 419) subgroups, mean monthly healthcare costs were $6,660, $7,443, and $17,330, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
First-year costs after diagnosis by payer: U.S. commercial and Medicare claims, 2016 to 2021
“The final analytic cohort included 3,700 patients with MG and 37,000 controls. On average, patients were aged 54 years, with 60% being female. The difference-in-difference estimates of the total health care cost for MG diagnosis in commercial and Medicare patients were $25,799 and $4,927, respectively (P < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs in newly diagnosed and previously diagnosed patients and around crisis events: U.S. claims, 2014 to 2019
“Mean HCRU and costs were higher for newly diagnosed patients compared with previously diagnosed patients (hospitalizations: 0.46 vs. 0.34; all-cause costs: $26,419.20 vs. $24,941.47; direct costs for gMG treatments: $9,890.37 vs. $9,186.47) and further increased for patients with exacerbation events (hospitalizations: 0.72; all-cause costs: $43,734.15; direct costs for gMG treatments: $21,550.02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients who experienced crisis events, HCRU and costs markedly increased during the 12 months immediately before the crisis event (hospitalizations: 1.35; all-cause costs: $49,236.68) compared with the 2 preceding years and increased further during the 12 months following the crisis index date (hospitalizations: 2.78; all-cause costs: $173,956.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs in patients treated with chronic IVIg or multiple nonsteroidal immunosuppressants
“Compared with the reference cohort (n = 2992), the MG crisis rate was approximately twice as high in both the chronic IVIg (n = 324) and multiple NSIST (n = 291) cohorts (p < 0.001); and the MG exacerbation rate was approximately four-fold higher in the chronic IVIg cohort (p < 0.001) and three-fold higher in the multiple NSIST cohort (p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median annual MG-related inflation-adjusted total healthcare costs were higher in the chronic IVIg ($81,900) and multiple NSIST ($30,300) cohorts than in the reference cohort ($2540).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs by glucocorticoid exposure: U.S. commercial claims
“Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incident GC toxicities were higher in patients with any GC use than those without (61.9% vs 52.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annual all-cause costs were >2x higher among patients with any GC use than those with no GC use ($76,381 vs $35,309). GC acute and chronic toxicities and costs tended to increase with increasing GC use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization trends: U.S. Nationwide Inpatient Sample and Medicare, 2010 to 2019
“Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all p < 0.001). Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Range of direct and indirect costs across studies: systematic reviews
“Across studies, the mean per-patient annual direct medical cost of illness was estimated at between $760 and $28,780, and cost per hospitalization between $2550 and $164,730. The indirect cost of illness was estimated at $80 and $3550.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs varied considerably by patient characteristics, and drivers of the direct medical cost of illness included intravenous immunoglobulin and plasma exchange, myasthenic crisis, mechanical ventilatory support, and hospitalizations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“1374 records were identified initially, and 44 were included in the final review.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Direct costs include treatment and follow-up in the primary and specialist health care. They were estimated to €3 500–12 000 per MG patient per year in the Nordic countries, similar in other European countries, and higher in United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intangible costs include value of lost life-years and reduced quality of life, which are rarely assessed, but have been estimated to be half of the total societal MG costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Generalized myasthenia gravis on families
Out-of-pocket costs and financial adjustments reported by U.S. patients and caregivers
“Eight hundred people with MG and 238 caregivers responding on behalf of a person with MG completed the survey.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“70% reported making financial adjustments or seeking financial assistance. Annual out-of-pocket costs (mean, $15,798; median, $7750) were primarily driven by medications, cost to receive a diagnosis, and healthcare insurance premiums. People receiving infusions paid significantly more across all care domains.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient and caregiver productivity losses by symptom severity: MyRealWorld MG
“In the MyRealWorld-MG study, 36.5% of MG patients reported taking sick leave within the last month and 11.4% reported stopping work (or retiring early) due to MG. Furthermore, 36.0% required caregiver support with 14.6% of caregivers reducing working hours and 13.4% stopping work.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with severe MG incurred 3.8 times more productivity losses compared to patients with mild disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual productivity losses per patient in the United States by MG-ADL category
Caregiver burden measured with the Zarit Burden Interview in five European countries
“A cross-sectional study design collected patient and caregiver data in Germany, Italy, Spain, the UK, and France.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers (N = 69) reported a mean ZBI-22 score of 24.3, with 40.6% reporting no burden, 47.8% mild-to-moderate burden, 8.7% moderate-to-severe burden, and 2.9% severe burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Informal caregivers of MG patients experience a substantial burden, impacting their physical, emotional, and financial well-being.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sick leave and need for caregiver help compared with the general population
“Taking sick leave in the past month was 2.6 times more frequent among people diagnosed with MG compared to the general population (34.4% vs. 13.2%) and four times more people diagnosed with MG reported needing help from a caregiver (34.8% vs. 8.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic concerns of U.S. adults with gMG facing social determinants of health barriers
“The survey was completed by 38 individuals living with gMG, the majority of whom were enrolled in public insurance and not employed. The most commonly reported major economic concerns were managing funds for emergency care (66%), loss of income (61%), and non-medical expenses (58%), highlighting the diversity of economic challenges.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Acetylcholine receptor antibody positivity required for enrollment in the phase 3 trial of claseprubart
Out-of-pocket cost of receiving a diagnosis reported by U.S. patients
Approaches to treatment
Current treatment options and standard of care
Acetylcholinesterase inhibitors
Pyridostigmine as initial symptomatic treatment: international consensus guidance
“Pyridostigmine should be part of the initial treatment in most patients with MG. Pyridostigmine dose should be adjusted as needed based on symptoms. The ability to discontinue pyridostigmine can be an indicator that the patient has met treatment goals and may guide the tapering of other therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Corticosteroids or IS therapy should be used in all patients with MG who have not met treatment goals after an adequate trial of pyridostigmine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pyridostigmine dosing, adverse effects, and second-line symptomatic agents: Nordic guidance
“Pyridostigmine represents the first‐line symptomatic treatment, while ambenonium and beta adrenergic agonists are second‐line options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pyridostigmine dosage is titrated individually, where 30–60 mg every 4–6 h is a typical adult dose” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a Dutch–Belgian cohort, 91% reported side effects from pyridostigmine, and one in four discontinued the treatment mainly due to side effects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pyridostigmine in optimal dose should be given as a first‐line symptomatic treatment in most patients with MG. The optimal dose can vary according to activity needs and be adjusted by the patient accordingly. Terbutaline and salbutamol can be used as adjuvant symptomatic treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA-labeled indication and dosing: pyridostigmine
Corticosteroids
Corticosteroid use and tapering: international consensus guidance
“Once patients achieve treatment goals, the corticosteroid dose should be gradually tapered. In many patients, continuing a low dose of corticosteroids long-term can help to maintain the treatment goal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because corticosteroids may cause transient worsening of myasthenic weakness, it may be appropriate to wait several days for PLEX or IVIg to have a beneficial effect before starting corticosteroids” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corticosteroid dosing and combination with a steroid-sparing agent: Nordic guidance
“Early high‐dose oral prednisone or prednisolone is recommended (0.75–1.00 mg/kg) in patients with moderate to severe generalized MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with mild to moderate generalized MG, steroids can be given at lower doses (0.25 mg/kg), followed by gradual escalation depending on the clinical response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A gradual increase of steroid dose from 5 to 10 mg daily over a few weeks is recommended to avoid an initial worsening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 75% of patients, steroids have an effect within 2–4 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the high risk of long‐term adverse effects and to further improve muscle weakness, corticosteroids should be combined with another immunosuppressive drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Daily rather than alternate-day dosing: British guideline update
Glucocorticoid exposure in US commercially insured adults with generalized myasthenia gravis
“Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Use of nonsteroidal immunosuppressants was higher among patients with GC use than those without (37.6% any GC use vs 19.6% no GC use).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonsteroidal immunosuppressive agents
Indications for and choice of nonsteroidal immunosuppressive agents: international consensus guidance
“A nonsteroidal IS agent should be used alone when corticosteroids are contraindicated or refused. A nonsteroidal IS agent should be used initially in conjunction with corticosteroids when the risk of steroid side effects is high based on medical comorbidities. A nonsteroidal IS agent should be added to corticosteroids when: a. Steroid side effects, deemed significant by the patient or the treating physician, develop; b. Response to an adequate trial (table e-1) of corticosteroids is inadequate; or c. The corticosteroid dose cannot be reduced due to symptom relapse.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonsteroidal IS agents that can be used in MG include azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, and tacrolimus. The following factors should be considered in selecting among these agents: a. There is widespread variation in practice with respect to choice of IS agent since there is little literature comparing them. b. Expert consensus and some RCT evidence support the use of azathioprine as a first-line IS agent in MG. c. Evidence from RCTs supports the use of cyclosporine in MG, but potential serious adverse effects and drug interactions limit its use. d. Although available RCT evidence does not support the use of mycophenolate and tacrolimus in MG, both are widely used, and one or both are recommended in several national MG treatment guidelines” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For nonsteroidal IS agents, once treatment goals have been achieved and maintained for 6 months to 2 years, the IS dose should be tapered slowly to the minimal effective amount.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate as a steroid-sparing agent: 2020 consensus update
“An RCT enrolled 50 patients with AChR-Ab+ MG taking prednisone at a dose of ≥10 mg/d. 34 Patients were randomized 1:1 to MTX 20 mg/wk or placebo. There was no difference in the primary outcome measure, the area under the prednisone dose-time curve between months 4 and 12, and the mean 12-month change in QMG, MMT, MG-Quality of life, MG-ADL, and MGC was no different between treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although evidence from RCTs is lacking, oral MTX may be considered as a steroid-sparing agent in patients with generalized MG who have not tolerated or responded to steroid-sparing agents that are better supported by RCT data” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Azathioprine first choice and onset of effect: Nordic guidance
“These drugs have a delayed response of 1 to 6 months, and the full effect is sometimes reached after more than 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Nordic countries, azathioprine (2–3 mg/kg) is usually the first‐line treatment in both adults and children. Mycophenolate (1–2 g daily), methotrexate (20 mg/week), and tacrolimus (3 mg daily) are secondary alternatives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Azathioprine is recommended as the first‐choice non‐steroidal immunosuppressant drug. Mycophenolate, methotrexate, and tacrolimus are recommended as secondary immunosuppressants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Thymectomy
Thymectomy in nonthymomatous AChR antibody-positive disease: 2020 consensus update
“In nonthymomatous, generalized MG patients with AChR-Ab, aged 18–50 years, thymectomy should be considered early in the disease to improve clinical outcomes and to minimize immunotherapy requirements and the need for hospitalizations for disease exacerbations (median 9, range 2–9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thymectomy should be strongly considered in patients with AChR-Ab+ generalized MG if they fail to respond to an initial adequate trial of immunotherapy or have intolerable side effects from that therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current evidence does not support an indication for thymectomy in patients with MuSK, low-density lipoprotein receptor–related protein 4, or agrin antibodies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MGTX randomized trial: 3-year results
“A total of 126 patients underwent randomization between 2006 and 2012 at 36 sites. Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001); patients in the thymectomy group also had a lower average requirement for alternate-day prednisone (44 mg vs. 60 mg, P<0.001). Fewer patients in the thymectomy group than in the prednisone-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized for exacerbations (9% vs. 37%, P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thymectomy improved clinical outcomes over a 3-year period in patients with nonthymomatous myasthenia gravis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MGTX extension: 5-year results
“Of 111 subjects who completed the 3-year MGTX trial, 68 (61%) entered the extension study between September 1, 2009 and August 26, 2015 (33 prednisone alone; 35 prednisone plus thymectomy).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years, patients randomised to thymectomy plus prednisone continued to demonstrate improved clinical status compared to patients in the prednisone alone group based on time-weighted average QMG (5.47±3.87 vs. 9.34±5.08; 95% CI for the difference 0.71–7.04; p=0.0007) and lower average alternate-day prednisone requirements (24 mg±21 mg vs. 48±29 mg; 95% CI for the difference 12–36 mg; p=0.0002). The proportion of patients requiring hospitalisation for MG exacerbation (6% vs. 30%; 95% CI for the difference 7.1–42.1%; p=0.0105) was lower in the thymectomy group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AAN practice advisory on thymectomy
“For patients with nonthymomatous AChR ab+ generalized MG, treatment with thymectomy plus prednisone is probably more effective than treatment with prednisone alone for increasing the chance of attaining minimal manifestation status (risk difference at 36 months, 20%; 95% confidence interval, 1.6%-37%; moderate confidence in the evidence).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Clinicians should discuss thymectomy treatment with patients with AChR ab+ generalized MG (Level B).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Timing of thymectomy by age: Nordic guidance
“In patients with non‐thymoma, generalized MG, AChR antibodies, and age below 50 years, thymectomy should be performed within 4 months from diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with non‐thymoma generalized MG, AChR antibodies, and age 50–65 years, early thymectomy should be considered if minimal manifestations are not reached, or the patient has substantial side effects from treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Minimally invasive techniques are preferred with fewer perioperative complications, shorter hospitalization time, and minimal scars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intravenous immunoglobulin and plasma exchange
Short-term and maintenance use: international consensus guidance
“PLEX and IVIg are appropriately used as short-term treatments in patients with MG with life-threatening signs such as respiratory insufficiency or dysphagia; in preparation for surgery in patients with significant bulbar dysfunction; when a rapid response to treatment is needed; when other treatments are insufficiently effective; and prior to beginning corticosteroids if deemed necessary to prevent or minimize exacerbations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IVIg and PLEX are probably equally effective in the treatment of severe generalized MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of IVIg as maintenance therapy can be considered for patients with refractory MG or for those in whom IS agents are relatively contraindicated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PLEX and IVIg are the mainstay of management in myasthenic crisis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Crisis treatment and maintenance immunoglobulin: Nordic guidance
“Plasma exchange and intravenous immunoglobulin are the primary treatments recommended for crisis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Immunoglobulins, given intravenously or subcutaneously, are rarely used as maintenance therapy. A recent study found no steroid‐sparing effect of intravenous immunoglobulin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of immunoglobulin in generalized myasthenia gravis
“We included 12 RCTs (11 with usable data; 515 participants) conducted between 1997 and 2025 in Europe, North America, and Asia. All studies assessed IVIg; none assessed SCIg. Comparators included PLEX (six trials), placebo (five trials), and corticosteroids (one trial).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We found low‐certainty evidence that IVIg may improve symptoms and functional capacity in the medium term in people with MG, compared to placebo, though the effects did not reach commonly used thresholds for clinical significance and were based on sensitivity analyses. Based on moderate‐certainty evidence, IVIg probably also increases the incidence of headache. Based on very low to low‐certainty evidence, IVIg may be less beneficial than PLEX for short‐term improvement in symptoms and may prolong hospital stay, though we found no differences in adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement c5 inhibitors
Eculizumab in refractory AChR antibody-positive disease: 2020 consensus update
“In a phase III international multicenter RCT of 125 patients with refractory generalized nonthymomatous AChR-Ab+ MG (REGAIN), the primary outcome measure of change in the MG-ADL score from baseline to week 26, measured by worst-rank analysis of covariance, was not significantly different ( p = 0.0698) between eculizumab and placebo arms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eculizumab should be considered in the treatment of severe, refractory, AChR-Ab+ generalized MG (median 9, range 2–9). The role of eculizumab in the treatment of MG is likely to evolve over time. Until further data become available to allow comparisons of cost and efficacy with other treatments, eculizumab should be considered after trials of other immunotherapies have been unsuccessful in meeting treatment goals (median 9, range 5–9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement inhibitors and FcRn blockers as second-line treatments: Nordic guidance
“Several inhibitors of complement proteins have appeared within the last 5 years as a new treatment modality for refractory or difficult‐to‐treat MG patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment effect is seen within the first 2 weeks and maximal effect appears within the first 2 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to high drug costs, complement and FcRn inhibitors are recommended only for difficult‐to‐treat patients with severe MG not responding to standard immunosuppressive treatment. Complement and FcRn inhibitors act fast, have a proven effect with an acceptable safety profile, with a selective impact on the immune system. If costs permit and are acceptable, they should be recommended as alternative second‐line treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eculizumab: FDA-labeled indication, dosing, and pivotal trial
Eculizumab biosimilars: FDA-labeled indication
Ravulizumab: FDA-labeled indication, dosing, and pivotal trial
Zilucoplan: FDA-labeled indication, dosing, and pivotal trial
Target of approved complement inhibitors
“To date, all FDA-approved drugs in this category focus on targeting the C5 convertase enzyme.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zilucoplan is a small macrocyclic peptide that not only binds to C5 to inhibit its cleavage, but also interferes with C5b binding to C6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neonatal fc receptor blockers
Mechanism, onset, and comparative effect of FcRn blockers: Nordic guidance
“Monoclonal antibodies directed at the FcRn receptor's binding site for IgG block recycling and lead to a 60%–70% reduction in circulating IgG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment can be tailored according to the disease state; new treatment cycles can be administered with signs of symptom worsening or according to a fixed schedule.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The number of treatment responders and the magnitude of the treatment response for FcRn blockers and complement inhibitors seem to be similar. No prospective and controlled head‐to‐head studies have been undertaken.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efgartigimod intravenous: FDA-labeled indication, dosing, and pivotal trials
Efgartigimod alfa and hyaluronidase subcutaneous: FDA-labeled indication and dosing
Rozanolixizumab: FDA-labeled indication, dosing, and pivotal trial
Nipocalimab: FDA-labeled indication, dosing, and pivotal trial
B-cell depleting antibodies
Rituximab in MuSK and refractory AChR antibody-positive disease: 2020 consensus update
“A phase II RCT of RTX (Beat-MG) enrolled 52 patients with generalized nonthymomatous AChR-Ab+ MG on a stable regimen of prednisone for 4 weeks or prednisone plus another IS agent for 6 months. 27 Two cycles of RTX 6 months apart were compared to placebo with the primary outcome being a steroid-sparing effect (≥75% reduction in mean daily prednisone requirements in the 4 weeks before week 52 compared with the 4-week period before randomization). The study was designed to assess futility (nonsuperiority). Preliminary results reported that the area under the curve for prednisone was not significantly different between RTX and placebo groups, with 60% on RTX and 56% on placebo achieving the primary outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rituximab should be considered as an early therapeutic option in patients with MuSK-Ab+ MG who have an unsatisfactory response to initial immunotherapy (median 9, range 4–9). The efficacy of RTX in refractory AChR-Ab+ MG is uncertain. It is an option if patients fail or do not tolerate other IS agents (median 8, range 4–9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rituximab as a first-line option in new-onset disease: Nordic guidance
“In RINOMAX, 47 Swedish patients with new‐onset generalized MG (96% AChR‐antibody MG) were randomized to receive 500 mg rituximab or placebo as an add‐on to the standard of care. [ 43 ] Minimal disease manifestations at 16 weeks, defined as a Quantitative Myasthenia Gravis (QMG) score of 4 or less with a prednisolone dose ≤10 mg and no rescue treatment, was the primary endpoint. This was met by 71% in the active arm and 29% in the placebo group ( p = 0.007).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rituximab should be considered a first‐line immunosuppressive drug in newly onset disease, as an alternative to steroids and azathioprine. Rituximab should be considered for treatment‐refractory symptoms, although evidence for its effectiveness is weaker than in newly onset disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early rituximab: British guideline update
“Randomised controlled trial evidence now supports early use of rituximab (within 1 year of generalised disease onset), although the evidence is less robust, but still likely to be useful, in established treatment-refractory MG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of rituximab in myasthenia gravis
“We included two RCTs with a total of 99 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rituximab's effects on symptom severity and functional ability in the long‐term are uncertain. The evidence suggests that rituximab results in little to no difference in its steroid‐sparing effect; however, it probably results in a large reduction in relapse requiring rescue therapy over nine months, based on results from two studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inebilizumab: FDA-labeled indication, dosing, and pivotal trial
Limitations of current therapies
Summary
10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and Tice et al. (2022) state that about 20,000 patients with generalized myasthenia gravis are estimated to be intolerant or to have an inadequate response to conventional treatment options. Upward of thirty percent of patients do not benefit from complement inhibition. In claims data from 8833 patients with generalized myasthenia gravis, incident glucocorticoid toxicities occurred in 61.9% of patients with any glucocorticoid use, compared with 52.3% without, and annual all-cause costs were more than twice as high ($76,381 vs $35,309). Soliris increases the risk of serious meningococcal infections, requires meningococcal vaccination at least 2 weeks before the first dose, and, like Zilbrysq, is available only through a REMS program. Vyvgart may increase the risk of infection. Gilhus et al. list the need for meningococcal vaccination before starting treatment, recommended pneumococcal vaccination, and regular intravenous or subcutaneous injections as limitations, and a company presentation states that 40% of patients discontinue Vyvgart within one year. ICER estimated an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG for eculizumab, and high drug costs limit access to complement inhibitors and FcRn blockers in most countries.
Refractory disease despite conventional immunosuppression
“Definition of refractory MG. PIS3 is unchanged or worse after corticosteroids and at least 2 other IS agents, used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning, as defined by patient and physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incomplete response to targeted biologics
“There remain upward of thirty percent of patients who do not benefit from complement inhibition, which demonstrates the importance of other mechanisms of autoantibody action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is a pressing need for such advancements, especially considering the proliferation of multiple costly treatment options with substantial minorities of patients showing a poor response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid toxicity and associated costs
“Incident GC toxicities were higher in patients with any GC use than those without (61.9% vs 52.3%). Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GC acute and chronic toxicities and costs tended to increase with increasing GC use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Meningococcal infection risk, vaccination, and REMS with complement C5 inhibitors
“One case of meningococcal meningitis occurred, despite vaccination in the OLE and the patient was successfully treated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vaccination against Neisseria meningitidis (both meningococcal conjugate Men ACWY and serogroup B or MenB) is required at least 2 weeks before starting treatment with eculizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration burden: infusion schedules and repeated injections
Treatment persistence with FcRn blockade: company-cited claims data
Cost and cost-effectiveness of targeted biologics
“For eculizumab, with an estimated annual cost of $653,100, the incremental cost-effectiveness ratio was $5,210,000 per QALY/evLYG (Table 2). For analyses of efgartigimod, we used a placeholder price of $418,400, which is the midpoint of the potential price range cited by the manufacturer.11 At this estimated price, efgartigimod has an the incremental cost per QALY/evLYG of $2,076,000 (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The price for eculizumab is extremely high and is distinctive for the amount by which it exceeds the price needed to reach traditional cost-effectiveness thresholds in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Very high drug costs have limited the accessibility to treatment in most countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In common with complement inhibitors, the availability of FcRn blockers is limited by high drug costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
The roles of complement and FcRn inhibitors are being established, especially in patients unresponsive to conventional therapy; Gilhus et al. (2024) recommend them, because of high drug costs, only for difficult-to-treat patients with severe myasthenia gravis not responding to standard immunosuppressive treatment, and as second- or third-line treatment in severe exacerbations and crisis. The company positions claseprubart as a potential first-line biologic intended to displace C5 complement inhibitors and compete with FcRn blockers, and notes that the C5 efficacy data it compares against come from different trials with different designs and populations. Its target profile is a single self-administered 300 mg/2 mL subcutaneous autoinjector dosed every 2 or 4 weeks, without a boxed warning or REMS; the every-4-week arm and a QMG inclusion criterion were added to the phase 3 trial after a post hoc analysis of MaGic. The company proposes that selective inhibition of the classical pathway may lower the risk of infection from encapsulated bacteria by preserving the lectin and alternative pathways.
Company positioning against complement C5 inhibitors and FcRn blockers
Company target product profile: no Boxed Warning or REMS and self-administered autoinjector
Every-4-week subcutaneous dosing evaluated in the phase 3 trial
Biologic market growth anticipated by the company
Guideline positioning of complement and FcRn therapies
“several clinical trials have been published for newer targeted therapies in MG, predominantly those that inhibit the complement and neonatal Fc gamma receptor pathways, the roles of which are being slowly established especially in patients unresponsive to conventional therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
MuSK antibody-positive disease: response to conventional therapies
“Many patients with MuSK-MG respond poorly to ChEIs, and conventional pyridostigmine doses frequently induce side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with MuSK-MG appear to respond well to corticosteroids and to many steroid-sparing IS agents. They tend to remain dependent on prednisone despite concomitant treatment with steroid-sparing agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MuSK-MG responds well to PLEX, while IVIg seems to be less effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MuSK antibody-positive disease: complement independence and thymectomy
“The observation of predominant IgG4 antibodies in patients with MuSK MG is indicative of immune response that corresponds with the IgG4 autoimmune diseases ( 9 ) and the antiinflammatory properties of the IgG4 that include the inability to activate complement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The thymus is normal ( 116 ), and thymectomy does not benefit patients with MuSK with MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rituximab response by antibody status
“A retrospective combined analysis of previously published case reports of 169 patients between January 2000 and August 2015 reported that 72% of MuSK-Ab + MG and 30% of AChR-Ab+ MG patients treated with RTX achieved MM status or better.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Seronegative disease: efgartigimod in anti-AChR antibody-negative adults
Antibody subgroups enrolled in FcRn blocker trials
Ocular versus generalized disease
“In 20% of MG patients, the muscle weakness remains confined to the extraocular muscles” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Claseprubart: baseline QMG subgroup in the phase 2 trial
Care management intervention strategies
Treatment goal of minimal manifestation status: international consensus guidance
“Goals for the treatment of MG. MGFA Task Force Post-Intervention Status (PIS) classification Minimal Manifestation Status (MMS) or better,3 with no more than grade 1 Common Terminology Criteria for Adverse Events (CTCAE) medication side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MMS: The patient has no symptoms or functional limitations from MG but has some weakness on examination of some muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal symptom expression as a patient-reported treatment goal
“‘Minimal symptom expression’ was defined as MG-ADL total score of 0–1 or MG-QOL15 total score of 0–3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MSE using the MG‐ADL shows promise in helping to determine success of treatment and may be the aspirational goal of MG treatment for the future once validated, particularly given the evolving treatment landscape in MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MSE, as a patient‐centric endpoint, can be used alongside clinician‐assessed measures and safety measures to support an integrated treatment goal that encompasses both efficacy and tolerability for the treatment of gMG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Steroid-sparing strategy and tapering
“A nonsteroidal IS agent should be used initially in conjunction with corticosteroids when the risk of steroid side effects is high based on medical comorbidities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tapering of IS drugs is associated with risk of relapse, which may necessitate upward adjustments in dose. The risk of relapse is higher in patients who are symptomatic, or after rapid taper. d. It is usually necessary to maintain some immunosuppression for many years, sometimes for life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with generalized MG should be given a non‐steroid immunosuppressant to achieve a better clinical response and enable steroid dose reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tapering of corticosteroids, and non‐steroidal immunosuppressants, should be considered after 1–2 years in patients in stable remission or with minimal symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring for adverse effects of immunosuppression
“Patients must be monitored for potential adverse effects and complications from IS drugs. Changing to an alternative IS agent should be considered if adverse effects and complications are medically significant or create undue hardship for the patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients on steroids should be monitored for blood pressure, body weight, bone mineral density, blood glucose levels, sleep, and mood problems.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to spontaneous disease fluctuations, comorbidities, and changes in life conditions, regular long‐term specialized follow‐up is needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring disease activity with MG-ADL and QMG
“The QMG takes up to 25 min to complete and requires technician training, a hand‐held dynamometer, a spirometer, and a stopwatch.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MG‐ADL is easy to administer, requires no additional training, is quick to complete (<10 min), and can be used in routine clinical practice or in clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 2‐point change seemed to provide the best balance between sensitivity (77%) and specificity (82%); thus, this analysis revealed that a 2‐point improvement in MG‐ADL score best indicated clinical improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physical training and shared goal setting: Nordic guidance
“Adapted physical training is recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients and doctors should together define ambitious treatment goals” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.